clinical trial · NCT06260748
A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX)
Leadiant Biosciences, Inc.·phase3·withdrawn
Cerebrotendinous XanthomatosesChenodeoxycholic acidChenodeoxycholic acid Placebo
brief summary
This study is designed to demonstrate the beneficial effect of CDCA in the treatment of CTX-associated diarrhea in approximately 10 participants aged 2-75 years old with newly diagnosed CTX or suspected CTX who have never received treatment with CDCA.
started
May 27, 2024
primary completion
Nov 30, 2025
completion
Dec 31, 2025
last updated
Nov 18, 2024
official title
A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Chenodeoxycholic Acid (CDCA), With an Open-Label Cohort, in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol